An interventional study of Hypo fractionated RT in Endometrial Cancer and Endometrial Adenocarcinoma, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. Recruiting at 1 site in Canada. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre · Not applicable, Interventional, and Treatment
Clinical experience with hypo fractionated radiotherapy to date has shown that it is a safe and effective way to treat many types of cancer. Hypo fractionation means that the patient receives a total of 5 radiation treatments every other day, rather than 25 treatments over 5 weeks.
The goal of this study is to find out how safe this special kind of radiation technique is for women with endometrial cancer, both right after the treatment and later on. We also want to see how well this treatment works in stopping the cancer from coming back and how it affects the patients' overall health and quality of life. The main question it aims to answer is:
How does this particular type of radiotherapy affect the patients in terms of short and long term side effects?
Participants will:
Uterine endometrial cancer poses a significant cause of morbidity and mortality as the sixth most common malignancy worldwide. The management of non-metastatic EC involves surgery, usually followed by adjuvant radiotherapy and/or adjuvant chemotherapy depending on the risk stratification. Radiation therapy can be delivered in the form of whole pelvic RT (WPRT), vaginal vault brachytherapy (VBT) or a combination of both techniques. Technological advancements now enable us to safely administer doses exceeding 2 Gy per fraction (hypofractionation), which can significantly reduce the treatment duration. By doing this, hypofractionation can save patient's time, reduce costs for the health system and reduce the load in radiotherapy units.
There is limited evidence assessing hypo fractionated regimens in gynecological malignancies, particularly in endometrial cancer. This protocol aims to assess the safety and efficacy of hypo fractionated adjuvant radiotherapy in endometrial cancer treated at the McGill University Health Centre (MUHC), reporting on acute toxicity, late toxicity, oncological outcomes, and quality of life.
1,347 studies on the registry are indexed under Endometrial Neoplasms; 452 are open to participants now.
This study's planned enrollment of 50 is below the median of 70 across 954 interventional studies indexed under Endometrial Neoplasms.
Browse Endometrial Neoplasms studies →McGill University Health Centre/Research Institute of the McGill University Health Centre is the lead sponsor of 420 studies on the registry; 106 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Hypo fractionated radiotherapy regimen in patients with EC receiving adjuvant WPRT.
Radiation: Hypo fractionated RT
The patients will receive whole pelvic radiotherapy (WPRT) to a total dose of 28.5 Gy in 5 fractions in alternate days (BED 64.6 Gy), delivered by RapidArc. Vaginal brachytherapy boost, 6 Gy in 1 fraction, is allowed in patients with cervical stroma involvement
Primary Outcome Measure
Primary outcome: acute and late toxicity rates as measured by CTCAE v5.0. Toxicity will be considered acute if present up to 6 months after treatment and late if present beyond 6 months. Toxicity reports will be released at a median of 3 years of follow-up.
Time frame: Three years
Started Mar 2025 (actual). Primary completion is estimated for Aug 2030, 65 months after the start.
Of 187 non-industry interventional studies with no phase under Endometrial Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 63. This study's planned 65 months is above that.
Counting every sponsor, half of 192 studies reached it within 36 months; a quarter within 19 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
McGill University Health Centre/Research Institute of the McGill University Health Centre →